Abstract Sepsis is a systemic inflammatory response syndrome (SIRS) when an infection is the etiology of SIRS. Our previous studies have indicated that the release of the sympathetic neurotransmitter, norepinephrine (NE), from the gut is increased in sepsis, and that NE potentiates endotoxin-induced tumor necrosis factor (TNF)-α upregulation via the A subtype of α 2 -adrenoceptors (i.e., α 2A -AR) expressed on the surface of Kupffer cells. A specific antagonist for α 2A -AR, 2-[(4,5-dihydro-1H-imidazol-2-yl) methyl]-2,3-dihydro-1-methyl-1H-isoindole maleate (BRL-44408 maleate), reduces TNF-α secretion in cultured Kupffer cells. We, therefore, hypothesize that administration of BRL-44408 maleate inhibits inflammatory responses and reduces organ injury in sepsis. To study this, sepsis was induced in male rats by cecal ligation and puncture (CLP). At 5 h after CLP, BRL-44408 maleate (0.3125, 0.625, 1.25, 2.5, or 5.0 mg/kg BW) or vehicle (1-ml normal saline) were administered intravenously over a period of 30 min. Blood and intestinal samples were collected at 20 h after CLP. Serum levels of TNF-α, interleukin (IL)-6, IL-10, keratinocyte-derived chemokine (KC), macrophage inflammatory protein-2 (MIP-2), liver enzymes (i.e., aspartate aminotransferase (AST) and alanine aminotransferase (ALT)), and lactate were measured. The intestinal levels of TNF-α, IL-6, and myeloperoxidase (MPO) activities were also analyzed. In additional groups of animals, the necrotic cecum was excised at 20 h post-CLP, and the 10-day survival was recorded. Our results showed that serum levels of proinflammatory cytokines (TNF-α and IL-6), anti-inflammatory cytokine (IL-10), chemokines (KC, MIP-2), liver enzymes (AST and ALT), lactate, and intestinal levels of TNF-α, IL-6, and MPO were significantly elevated at 20 h after CLP. Administration of BRL-44408 maleate significantly reduced serum levels of proinflammatory cytokines, chemokines, liver enzymes, and lactate, and dramatically decreased TNF-α, IL-6, and MPO levels in the gut. However, it has no statistical effects on the elevated serum levels of IL-10. Moreover, BRL-44408 maleate at the doses of 2.5 or 5.0 mg/kg BW significantly increased the survival rate after CLP and cecal excision. In conclusion, modulation of the sympathetic nervous system by blocking α 2A -AR appears to be a novel treatment for inflammatory conditions such as sepsis.
Introduction
Despite the increased understanding of the complex pathophysiology of sepsis and the discovery of new treatments, severe sepsis still results in significant morbidity and mortality [1] [2] [3] [4] . Evidence indicates that in the USA alone, more than 750,000 people develop sepsis each year with an overall mortality of 28.6% [5] . A recent analysis of hospital records indicates that the total number of patients who have died of sepsis is actually increasing [2] . As the American population ages, it is anticipated that the occurrence of sepsis and subsequent mortality will significantly increase. Although activated protein C [APC, Drotrecogin alpha (activated), Xigris®, marketed by Eli Lilly] is the only Food and Drug Administration (FDA)-approved specific treatment for sepsis, it cannot be used in patients at risk for bleeding, in infants, and in immunosuppressed patients, especially those with thrombocytopenia or neutropenia, due to its adverse effects on coagulation [1, 6] . Moreover, even in the highly selected septic patients, APC only provides a relatively modest survival benefit [6] . As such, there is an urgent unmet medical need for an effective novel therapy for septic patients.
Our previous studies have demonstrated that the release of the sympathetic neurotransmitter, norepinephrine (NE), from the gut is increased in sepsis [7] , and that inhibition of the sympathetic nervous activity is beneficial in a rat model of polymicrobial sepsis [8] . NE potentiates endotoxininduced tumor necrosis factor (TNF)-α upregulation via the A subtype of α 2 -adrenoceptors (i.e., α 2A -AR) expressed on the surface of Kupffer cells [9] . In cultured Kupffer cells, NE increases the release of TNF-α, and a specific α 2A -AR antagonist, 2-[(4,5-dihydro-1H-imidazol-2-yl) methyl]-2,3-dihydro-1-methyl-1H-isoindole maleate (BRL-44408 maleate) [10] , reduces TNF-α secretion [9] . However, it remains unknown whether administration of BRL-44408 maleate after the onset of sepsis (i.e., posttreatment) reduces sepsis-induced organ dysfunction in rats. This study was conducted to test the hypothesis that delayed administration of BRL-44408 maleate inhibits inflammatory responses and reduces organ injury in sepsis.
Materials and methods
Animal model of sepsis Male Sprague-Dawley rats (275-375 g) were housed in a temperature-controlled room on a 12-h light/dark cycle and fed a standard Purina rat chow diet. Prior to the induction of sepsis, rats were fasted overnight, but allowed water ad libitum. Rats were anesthetized with isoflurane inhalation, and the ventral neck, abdomen, and groin were shaved and washed with 10% povidone iodine. Cecal ligation and puncture (CLP) was performed as we previously described [11] [12] [13] . Briefly, a 2-cm midline abdominal incision was performed. The cecum was exposed, ligated just distal to the ileocecal valve to avoid intestinal obstruction, punctured twice with an 18-gauge needle, squeezed slightly to allow a small amount of fecal matter to flow from the holes, and then returned to the abdominal cavity, following which, the abdominal incision was closed in layers. Sham-operated animals (i.e., control animals) underwent the same procedure with the exception that the cecum was neither ligated nor punctured. The animals were resuscitated with 3 ml/100 g BW normal saline subcutaneously immediately after surgery. The animals were then returned to their cages. All experiments were performed in accordance with the National Institutes of Health guidelines for the use of experimental animals. This project was approved by the Institutional Animal Care and Use Committee of the Feinstein Institute for Medical Research.
Administration of BRL-44408 maleate At 5 h after CLP, the left femoral vein was cannulated with a polyethylene-50 tubing under isoflurane anesthesia. Various doses of BRL-44408 maleate (0.3125, 0.625, 1.25, 2.5, or 5.0 mg/kg BW; Tocris Bioscience, Ellisville, MO, USA) in a volume of 1 ml normal saline or 1 ml normal saline (vehicle) were administered intravenously via the femoral catheter over 30 min at a constant infusion rate. Blood samples were collected at 20 h after sham operation or CLP and placed on ice to allow clotting. The samples were then centrifuged at 1,200 g for 10 min at 4°C, and the serum samples were stored at −80°C until assayed. An approximately 5-cm long jejunal segment was harvested from each animal at 20 h after CLP or sham operation and stored at −80°C until assayed.
Determination of tumor necrosis factor (TNF)-α, interleukin (IL)-6, IL-10, keratinocyte-derived chemokine (KC), and macrophage inflammatory protein (MIP)-2 The intestinal samples were excised, rinsed of blood, homogenized with polytron in an ice-cold lysis buffer (1% Triton X-100 in TBS with protease inhibitors, pH 7.5) and sonicated 30 s on ice. The tissue lysates were centrifuged at 12,000 rpm for 10 min, and protein concentration was measured by using Bio-Rad DC Protein Assay Kit (Bio-Rad, Hercules, CA, USA). TNF-α and interleukin (IL)-6 in the gut and serum were quantified with the use of specific enzymelinked immunosorbent assay (ELISA) kits according to the instructions provided by the manufacturer (BD Biosciences Pharmingen, San Diego, CA, USA). Intestinal levels of TNF-α and IL-6 were normalized to the protein concentration in the sample. Serum levels of IL-10, KC, and macrophage inflammatory protein (MIP)-2 were measured using rat IL-10 ELISA kit (BD Biosciences Pharmingen), Quantikine KC ELISA kit (R&D Systems, Minneapolis, MN, USA), and MIP-2 ELISA kit (ALPCO Diagnostics, Salem, NH, USA), respectively, as per the manufacturers' instructions.
Measurement of myeloperoxidase (MPO) activity Neutrophil accumulation in the gut was estimated using the myeloperoxidase (MPO) activity assay as we described previously [14] . Briefly, samples of 100 mg were suspended in 1 ml of 0.5% hexadecyltrimethylammonium bromide in 50 mmol/L phosphate buffer (pH 6.0) and sonicated 90 s on ice. Homogenates were cleared by centrifuging at 12,000 rpm for 10 min at 4°C, and the protein concentration of supernatants was determined by using Bio-Rad DC Protein Assay Kit (Bio-Rad, Hercules, CA, USA). The reaction was carried out in a 96-well plate by adding 290 µl of 50 mmol/L phosphate buffer with 3 µl substrate solution (containing 20 mg/ml o-dianisidine hydrochloride) and 3 µl H 2 O 2 (20 mmol/L). Sample (10 µl) was added to each well to start the reaction. Plates were read spectrophotometrically at 460 nm for 3 min on CERES UV 900C Microplate reader (Bio-Tek Inst Inc, Winooski, VT, USA). MPO activity (1 unit defined as change in absorbance of one per minute) was expressed as units per gram of tissue.
Determination of serum levels of transaminases and lactate Serum concentrations of alanine aminotransferase (ALT), aspartate aminotransferase (AST), and lactate were determined by using assay kits according to the manufacturer's instructions (Pointe Scientific Inc., Canton, MI, USA).
Survival study In additional groups of animals, various doses of BRL-44408 maleate (1.25, 2.5, or 5.0 mg/kg) in a volume of 1 ml normal saline or 1 ml normal saline (vehicle) were administered as described above at 5 h after CLP. At 20 h after CLP, the necrotic cecum was excised, and the abdominal cavity was washed twice with 40 ml of warm, sterilized normal saline solution. The abdominal incision was closed in layers. The procedure of cecal excision in CLP animals was performed to mimic the clinical situation in which septic focus is removed whenever possible. The animals then were allowed food and water ad libitum. All surviving animals were sacrificed on day 10.
Statistical analysis All data are expressed as means ± SE, with n=6 animals per group and compared by one-way analysis of variance (ANOVA) and Student-NewmanKeuls method. The survival rate, with n=20 animals, was estimated by Kaplan-Meier method and compared by the log-rank test. Differences in values were considered significant if P<0.05.
Results
BRL-44408 maleate downregulates proinflammatory cytokines after CLP As indicated in Fig. 1a , serum levels of TNF-α increased by 14-fold at 20 h after CLP (P<0.05). All three doses of BRL-44408 maleate treatment decreased serum TNF-α levels by over 60% (P<0.05). Similarly, circulating levels of IL-6 increased by 71-fold at 20 h after CLP; BRL-44408 maleate treatment significantly reduced IL-6 levels in a dose-dependent manner (P<0.05, Fig. 1b ). As shown in Fig. 2a and b, intestinal levels of TNF-α and IL-6 increased by 8.9-fold and 4.3-fold, respectively, at 20 h after CLP (P<0.05). Administration of all three doses of BRL-44408 maleate decreased intestinal TNF-α levels significantly (P<0.05, Fig. 2a) . However, the effects of BRL-44408 maleate on intestinal TNF-α levels are not in a clear dose-dependent manner. Administration of 1.25 or 2.5 mg/kg BW BRL-44408 maleate decreased intestinal IL-6 levels by 39% and 35%, respectively. However, these decreases were not statistically significant. When 5.0 mg/kg BW BRL-44408 maleate was administered, intestinal IL-6 levels were significantly reduced by 68% (P < 0.05, Fig. 2b ).
BRL-44408 maleate reduces serum chemokine levels and neutrophil infiltration in the gut after CLP As shown in Fig. 3a and b, dramatic increases in serum levels of KC and MIP-2 were observed at 20 h after CLP (P<0.05). Administration of all three doses of BRL-44408 maleate decreased serum KC and MIP-2 levels by over 65%. However, the effects of BRL-44408 maleate on chemokine levels are not in a clear dose-dependent manner. The level of MPO activity is an indicator of neutrophil infiltration. As demonstrated in Fig. 4 , intestinal levels of MPO activities increased significantly at 20 h after CLP. Treatment with BRL-44408 maleate inhibited the increase in intestinal MPO activities after CLP (P<0.05). Since the correlation of chemokine levels and MPO levels has been very well established [15] , we did not perform such an analysis in this study.
BRL-44408 maleate has no effect on anti-inflammatory cytokine IL-10 after CLP As indicated in Fig. 5 , serum levels of IL-10 increased by 10.7-fold at 20 h after CLP (P<0.05). Administration of BRL-44408 maleate had no significant effects on the elevated serum levels of IL-10.
BRL-44408 maleate attenuates organ injury after CLP Consistent with previous studies [13] , significant increases in liver enzymes (ALT and AST) were observed at 20 h after CLP (Fig. 6a, b) , indicating hepatic injury. All three doses of BRL-44408 maleate treatment significantly attenuated the increased levels of ALT. Administration of 1.25 or 2.5 mg/kg BW BRL-44408 maleate decreased AST levels by 30% and 37%, respectively. However, these decreases were not statistically significant. When 5.0 mg/kg BW BRL-44408 maleate was administered, serum AST levels were significantly reduced by 51% (P<0.05, Fig. 6b ). Serum levels of lactate, a marker for systemic hypoxia, increased by 358% at 20 h after CLP, and administration of BRL-44408 maleate decreased lactate levels (P<0.05, Fig. 5c ).
Effects of lower doses of BRL-44408 maleate on inflammatory responses and organ injury after CLP As showed above, the beneficial effect of BRL-44408 maleate in sepsis is not dose-dependent. To determine the effect of lower doses of BRL-44408 maleate in sepsis, 0.3125 or 0.625 mg/kg BW BRL-44408 maleate was administered at 5 h after CLP. Blood and gut samples were collected at 20 h after CLP for various measurements. As shown in Table 1 , administration of 0.3125 or 0.625 mg/kg BRL-44408 is not as effective as administration of 1.25 mg/kg BRL-44408 or higher doses in this rat model of sepsis.
BRL-44408 maleate improves survival after CLP It is almost impossible to fully confirm the beneficial effect of BRL-44408 maleate without the assessment of each organ system. However, it is practically impossible to do so in a single study. In such, we have conducted the survival study to determine the systemic and long-term beneficial effect of BRL-44408 maleate in sepsis. As shown in Fig. 7 , the survival rate after CLP and cecal excision in vehicle-treated animals was 60% at day 3 and decreased to 45% at days 4-10. Administration of 1.25 mg/kg of BRL-44408 maleate improved the survival rate to 60%. However, this increase was not statistically significant. When 2.5 or 5.0 mg/kg BW BRL-44408 maleate was administered, the survival rates were significantly increased to 85% and 80%, respectively (P<0.05, Fig. 7 ).
Discussion
An appropriate inflammatory response eliminates the invading microorganisms without causing damage to tissues, organs, or other systems. However, excessive and sustained inflammatory responses can lead to severe tissue damage. Overproduction of proinflammatory cytokines (e.g., TNF-α and IL-6) [16, 17] and chemokines (e.g., KC and MIP-2) [15, 18] have been implicated to play an important role in producing organ dysfunction in sepsis. Physicians and scientists have therefore focused on the elimination of the potentially detrimental proinflammatory mediators. In the past, various efforts have been made to inhibit cytokines such as TNF-α in septic patients by utilizing antibodies or soluble receptors. Unfortunately, the results have been generally disappointing and interspersed with some spectacular failures and unexpected toxicities [19] . The failed clinical trials may be caused by the possibility that the complete elimination of inflammatory cytokines is detrimental. In the present study, we demonstrate a novel approach to treat sepsis: to modulate proinflammatory mediators, but not directly block them, by the use of the α 2A -adrenoceptor antagonist. As such, our strategy represents an innovative approach in the field of preclinical development of anti-sepsis drugs. Using a rat The interaction between the central nervous system and immune system under various inflammatory diseases has found considerable interest in the past few decades. It is now widely accepted that the vagus nerve can inhibit the proinflammatory response [20, 21] . However, sympathetic influence on immune function is far more complicated. The adrenergic effects of the sympathetic nervous system are mediated through nine different adrenoceptors: three α 1 receptors (α 1A , α 1B , and α 1C ), three α 2 receptors (α 2A , α 2B , and α 2C ), and three β receptors (β 1 , β 2 , and β 3 ). Catecholamines possess both anti-inflammatory and proinflammatory activities.
The adrenergic anti-inflammatory effects are mostly mediated by β 2 -adrenoceptors [22, 23] , whereas stimulation of α 2 -adrenoceptors by α 2 -adrenergic agonists shows proinflammatory effects [24] . Only supraphysiologic levels of NE can inhibit cytokine release from monocytes/macrophages [9] . Many studies focusing on the immunomodulation by NE used high concentrations of NE (i.e., 10
and thus were more likely to activate β 2 -receptors that override α 2 -receptor-mediated proinflammatory responses [25] [26] [27] . Our previous studies have shown that intraportal injection of NE, at concentrations found under septic conditions (approximately 20 nM), produced an increase of circulating levels of proinflammatory cytokines (e.g., TNF-α and IL-6), similar to that found in sepsis [24, 28, 29] . This dose of NE (i.e., 20 nM) did not alter cardiac output [29] , suggesting that the NE concentration in the circulation was low enough not to influence β-receptormediated cardiac performance. This further implies that α 2 -adrenoceptors on Kupffer cells/macrophages become selectively activated in sepsis [23] . Through in vitro experiments with selective α-adrenergic inhibitors, we later found that the α 2A -AR subtype on Kupffer cells is responsible for the increased cytokine release [9] . Moreover, the receptor distribution pattern on Kupffer cells changes during the course of sepsis by increasing proinflammatory α 2A -AR expression while showing no changes in the expression of the other two α 2 -AR subtypes α 2B and α 2C [9] . Thus, these highly specialized macrophages express a different pattern of adrenoceptors and display a differential response to catecholamines, which drives the noradrenergic effect towards a systemic proinflammatory response. The result that systemic application of the α 2A -AR inhibitor BRL-44408 maleate inhibited the proinflammatory response in sepsis further confirms this concept. Since elevated levels of proinflammatory cytokines (e.g., TNF-α and IL-6) and chemokines inhibit cardiac function [30, 31] , damage the liver [16, 17] , and potentiate lung injury [32] , we believe that downregulation of proinflammatory responses (in a non-IL-10-dependent manner) plays an important role in the beneficial effect of BRL-44408 in sepsis. Our previous study has shown that prior reduction of Kupffer cell numbers, through the use of gadolinium chloride, prevents the increase in plasma levels of proinflammatory cytokines and the occurrence of cell dysfunction in sepsis [33] . However, the data in this manuscript cannot prove that the beneficial effect of BRL-44408 maleate is primarily mediated through Kupffer cells. Human sepsis is usually caused by a nidus of infection with replicating bacteria (e.g., pneumonia or intraabdominal abscess) that persists for an extended time. A wide variety of animal models has been developed to simulate human sepsis in order to reduce the covariate factors inherent in human investigations. In this study, we have utilized the rat model of CLP to produce polymicrobial sepsis. This model of sepsis is considered to be clinically relevant since it mimics many features of clinical peritonitis-sepsis. It is associated with an early, hyperdynamic phase (i.e., 2-10 h after CLP; characterized by an increased cardiac output and tissue perfusion, decreased vascular resistance, and hyperglycemia), which is followed by a late, hypodynamic phase (16 h after CLP and later; characterized by reduced cardiac output and tissue perfusion, increased vascular resistance, and hypoglycemia) [16, 34, 35] . We chose to treat septic rats at 5 h after CLP, because proinflammatory cytokines such as TNF-α and IL-6 increase significantly at 5 h after CLP [36] . Since severe sepsis occurred at 20 h post-CLP [34, 35] , we choose this time point to assess organ injury. In the current study, we have investigated the dose-dependent effect of BRL-44408 maleate using the rat CLP model of sepsis. Although not all the parameters were improved in a dosedependent manner, the higher dose groups seem to show better protection than the lower dose group. Most importantly, administration of less than 1.25 mg/kg BW BRL-44408 maleate at 5 h after CLP failed to significantly inhibit inflammatory responses. It appears that 2.5 mg/kg BW or higher doses of BRL-44408 maleate are required to improve survival in sepsis. Although the optimal dose of BRL-44408 maleate could not be fully established using the rat model of sepsis, the dose of 2.5 mg/kg BW produced the best survival protection. In the future, we will also verify these findings using other models of sepsis and determine the therapeutic window of this compound under such conditions. To advance this project into clinical trials, the full-scale pharmacokinetic as well as toxicological properties of BRL-44408 maleate will also be investigated.
In summary, a proinflammatory state and severe tissue injury were present at 20 h after CLP. Administration of BRL-44408 maleate, a specific α 2A -AR antagonist, at 5 h after CLP not only inhibited the proinflammatory response but also attenuated tissue injury and improved survival. Thus, modulation of the sympathetic nervous system by blocking α 2A -AR appears to be a novel treatment for sepsis and septic shock. We believe that the current study is an important step towards further development of BRL-44408 maleate as a novel therapeutic approach for patients with sepsis.
